newsfilter
← Earnings
Earnings Releases·

4D Molecular Therapeutics — Q3 2026 Earnings Summary

  • Collaboration and license revenue surged to $4.1 million in Q3 2026 from $0.1 million in Q3 2025, while net loss widened to $78.1 million from $56.9 million due to increased R&D expenses driven by 4D-150 Phase 3 execution.
  • Cash and marketable securities decreased to $375.0 million as of September 30, 2026, from $514.0 million at year-end 2025, with current resources and Otsuka collaboration payments projected to fund operations through the second half of 2028.
  • Management anticipates 2027 as a transformative year following expected topline data from 4FRONT-1 (Q2 2027) and 4FRONT-2 (H2 2027) Phase 3 trials in wet AMD, alongside an update on the 4D-710 Cystic Fibrosis trial at year-end.
  • Strategic progress includes the completion of randomization for the 4FRONT-2 wet AMD trial and the initiation of the 4SIGHT Phase 3 trial for 4D-150 in Diabetic Macular Edema (DME), expanding the candidate's pipeline into a second major retinal market.
Company
4D MOLECULAR THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology